ZTS

Zoetis Inc. (ZTS) Q1 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2025. Zoetis Inc. is a global leader in the animal health industry, operating in two geographic segments: the United States and International. The company markets products for companion animals (dogs, cats, horses) and livestock (cattle, poultry, swine, fish, sheep) across seven major categories, including parasiticides, vaccines, and dermatology. Notably, the company completed the divestiture of its medicated feed additive portfolio on October 31, 2024.

Key Financial Metrics

Note: Free Cash Flow calculated as Operating Cash Flow less Capital Expenditures ($149 million).

Material Changes vs. Prior Period

• Revenue Growth: Reported revenue increased 1% year-over-year. On an operational basis (excluding foreign exchange), revenue grew 5%, driven by approximately 4% price growth and 4% volume growth from key franchises. Foreign exchange headwinds reduced reported revenue by approximately 4%.
• Segment Performance:
  • U.S. Segment: Revenue increased 2% ($1,183M). Companion animal revenue grew 8% (driven by Simparica Trio, Librela, Solensia, and diagnostics), while livestock revenue declined 21% due to the prior-year medicated feed additive divestiture.
  • International Segment: Revenue was flat ($1,008M). Operational revenue grew 7%, but was offset by a 7% negative impact from foreign exchange (notably the Brazilian real, euro, and Mexican peso).
• Profitability: Net income rose 5% to $631 million. Cost of sales as a percentage of revenue improved to 28.0% from 29.4%, aided by price increases and the divestiture of lower-margin feed additives. However, the effective tax rate increased to 22.1% due to higher discrete tax expenses and a less favorable jurisdictional mix of earnings.
• Shareholder Returns: The company repurchased 2.7 million shares for $443 million and declared a quarterly dividend of $0.50 per share (up from $0.432 in Q1 2024).

Guidance, Outlook, and Risks

Management Commentary: Management highlighted strong operational growth driven by price realization and volume in key companion animal franchises. The company continues to invest in R&D ($157 million) and capital expenditures ($149 million) to support future growth. No specific full-year 2025 financial guidance was provided in this text excerpt.

Risks and Contingencies:

• Tariffs and Trade: The company faces uncertainty regarding new tariffs announced by the U.S. government in early 2025 and reciprocal actions by other nations, which could increase costs and negatively impact demand.
• Tax Audit: The IRS has issued a Notice of Proposed Adjustment regarding the 2018 U.S. Federal Income Tax return, proposing an additional liability of approximately $450 million. Zoetis disagrees with the position and is defending it; the company believes its current accrual is appropriate.
• Foreign Exchange: Significant exposure to currency fluctuations, with 42% of revenue denominated in foreign currencies.
• Legal Proceedings: Ongoing environmental litigation in Brazil (Ulianopolis) regarding waste disposal, though management believes defenses are strong.

Investor Verification Checklist

• Operational vs. Reported Growth: Verify the sustainability of the 5% operational revenue growth given the 4% foreign exchange headwind and potential tariff impacts.
• Tax Liability Exposure: Review the status of the IRS audit regarding the 2018 tax return and the adequacy of the $450 million proposed adjustment reserve.
• Debt Maturity Wall: Confirm refinancing plans for the $1.35 billion in debt maturing in 2025 (4.500% and 5.400% senior notes).
• Divestiture Impact: Assess the long-term revenue impact of the medicated feed additive divestiture on the livestock segment, particularly in the U.S.
• Share Repurchase Pace: Monitor the remaining $5.2 billion authorization under the share repurchase program and its impact on cash liquidity.